ABL2 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains ABL2 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

ACVR1B is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains ACVR1B status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

ALK is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains ALK status and glioblastoma as inclusion criteria, 1 is early phase 1 (0 open) [3].

APC is an inclusion eligibility criterion in 2 clinical trials for glioblastoma, of which 1 is open and 1 is closed. Of the trials that contain APC status and glioblastoma as inclusion criteria, 2 are phase 1 (1 open) [3].

ASXL1 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains ASXL1 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

ATM is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains ATM status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

ATR is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains ATR status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

ATRX is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains ATRX status and glioblastoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

BLM is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains BLM status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

BRAF is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains BRAF status and glioblastoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

BRCA1 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains BRCA1 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

BRCA2 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains BRCA2 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

CDK12 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains CDK12 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

CDK4 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and glioblastoma as inclusion criteria, 1 is early phase 1 (1 open) [3].

CDK6 is an inclusion eligibility criterion in 2 clinical trials for glioblastoma, of which 2 are open and 0 are closed. Of the trials that contain CDK6 status and glioblastoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (1 open) [3].

CDKN1A is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1A status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

CDKN1B is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1B status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

CDKN2A is an inclusion eligibility criterion in 4 clinical trials for glioblastoma, of which 2 are open and 2 are closed. Of the trials that contain CDKN2A status and glioblastoma as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (0 open), and 2 are phase 2 (1 open) [3].

CDKN2B is an inclusion eligibility criterion in 3 clinical trials for glioblastoma, of which 2 are open and 1 is closed. Of the trials that contain CDKN2B status and glioblastoma as inclusion criteria, 1 is early phase 1 (1 open) and 2 are phase 2 (1 open) [3].

CDKN2C is an inclusion eligibility criterion in 2 clinical trials for glioblastoma, of which 1 is open and 1 is closed. Of the trials that contain CDKN2C status and glioblastoma as inclusion criteria, 2 are phase 2 (1 open) [3].

CHD4 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains CHD4 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

CTDNEP1 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains CTDNEP1 status and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CTNNB1 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains CTNNB1 status and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CYLD is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains CYLD status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

DDX3X is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains DDX3X status and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

DICER1 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains DICER1 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

DNMT3A is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains DNMT3A status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

EGFR is an inclusion eligibility criterion in 22 clinical trials for glioblastoma, of which 14 are open and 8 are closed. Of the trials that contain EGFR status and glioblastoma as inclusion criteria, 10 are phase 1 (6 open), 3 are phase 1/phase 2 (2 open), 8 are phase 2 (5 open), and 1 is phase 2/phase 3 (1 open) [3].

ERBB2 is an inclusion eligibility criterion in 2 clinical trials for glioblastoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

ERBB3 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB3 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

EZH2 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains EZH2 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

FGF19 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains FGF19 status and glioblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF9 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains FGF9 status and glioblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and glioblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGFR2 is an inclusion eligibility criterion in 2 clinical trials for glioblastoma, of which 1 is open and 1 is closed. Of the trials that contain FGFR2 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [3].

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and glioblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGFR4 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR4 status and glioblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FLT3 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains FLT3 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

GATA3 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains GATA3 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

GLI2 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains GLI2 status and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

H3F3A is an inclusion eligibility criterion in 3 clinical trials for glioblastoma, of which 3 are open and 0 are closed. Of the trials that contain H3F3A status and glioblastoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 3 (1 open) [3].

HGF is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains HGF status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

IDH1 is an inclusion eligibility criterion in 2 clinical trials for glioblastoma, of which 1 is open and 1 is closed. Of the trials that contain IDH1 status and glioblastoma as inclusion criteria, 2 are phase 1 (1 open) [3].

IDH2 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

KDM6A is an inclusion eligibility criterion in 2 clinical trials for glioblastoma, of which 1 is open and 1 is closed. Of the trials that contain KDM6A status and glioblastoma as inclusion criteria, 2 are phase 1 (1 open) [3].

KDR is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains KDR status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

KEAP1 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains KEAP1 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

KIT is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains KIT status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

KMT2C is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains KMT2C status and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

KMT2D is an inclusion eligibility criterion in 2 clinical trials for glioblastoma, of which 1 is open and 1 is closed. Of the trials that contain KMT2D status and glioblastoma as inclusion criteria, 2 are phase 1 (1 open) [3].

KRAS is an inclusion eligibility criterion in 3 clinical trials for glioblastoma, of which 1 is open and 2 are closed. Of the trials that contain KRAS status and glioblastoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (0 open) [3].

LRP1B is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains LRP1B status and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAGI2 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains MAGI2 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MAP3K1 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains MAP3K1 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MDM4 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MED12 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains MED12 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MET is an inclusion eligibility criterion in 3 clinical trials for glioblastoma, of which 1 is open and 2 are closed. Of the trials that contain MET status and glioblastoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

MSH2 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains MSH2 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MSH6 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains MSH6 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MYC is an inclusion eligibility criterion in 2 clinical trials for glioblastoma, of which 1 is open and 1 is closed. Of the trials that contain MYC status and glioblastoma as inclusion criteria, 2 are phase 1 (1 open) [3].

MYCL is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains MYCL status and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MYCN is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

NF1 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains NF1 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NF2 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains NF2 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NOTCH1 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains NOTCH1 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NOTCH2 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains NOTCH2 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NRAS is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains NRAS status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NSD1 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains NSD1 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

OTX2 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains OTX2 status and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains PDGFRA status and glioblastoma as inclusion criteria, 1 is phase 2 (0 open) [3].

PIK3C2B is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3C2B status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

PIK3CA is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3CA status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

PIK3CB is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3CB status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

PIK3R1 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3R1 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

PPM1D is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains PPM1D status and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PTCH1 is an inclusion eligibility criterion in 2 clinical trials for glioblastoma, of which 1 is open and 1 is closed. Of the trials that contain PTCH1 status and glioblastoma as inclusion criteria, 2 are phase 1 (1 open) [3].

PTEN is an inclusion eligibility criterion in 3 clinical trials for glioblastoma, of which 1 is open and 2 are closed. Of the trials that contain PTEN status and glioblastoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

PTPN11 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains PTPN11 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

PVT1 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains PVT1 status and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RB1 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains RB1 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

RELA is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains RELA status and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RUNX1 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SETD2 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains SETD2 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SHH is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains SHH status and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

SMARCA4 is an inclusion eligibility criterion in 2 clinical trials for glioblastoma, of which 1 is open and 1 is closed. Of the trials that contain SMARCA4 status and glioblastoma as inclusion criteria, 2 are phase 1 (1 open) [3].

SMO is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains SMO status and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

SNCAIP is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains SNCAIP status and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

SOX9 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains SOX9 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

STAG2 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains STAG2 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SUFU is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains SUFU status and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

TAF1 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains TAF1 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

TBX3 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains TBX3 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

TERT is an inclusion eligibility criterion in 4 clinical trials for glioblastoma, of which 4 are open and 0 are closed. Of the trials that contain TERT status and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [3].

TET2 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains TET2 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

TNFRSF10B is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains TNFRSF10B status and glioblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TP53 is an inclusion eligibility criterion in 4 clinical trials for glioblastoma, of which 1 is open and 3 are closed. Of the trials that contain TP53 status and glioblastoma as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (0 open) [3].

XPO1 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains XPO1 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [3].

YAP1 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains YAP1 status and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ZMYM3 is an inclusion eligibility criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains ZMYM3 status and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].